SLC5A2 and heart failure: The 2022 guidelines from the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) now include a Class I recommendation to initiate SGLT2 inhibitors for preventing heart failure-related hospitalization and cardiovascular death in patients with heart failure with a reduced ejection fraction (HFrEF).